-
Halozyme CEO targets M&A and new deals as IRA uncertainty on pharma subsides
14 Oct 2025 14:22 GMT
… before landing on Elektrofi, Halozyme CEO Helen Torley said during an … long, durable revenues, the Halozyme chief executive explained.
Despite Hypercon and Halozyme … Alteogen signed with AstraZeneca and Daiichi Sankyo for its human recombinant hyaluronidase …
-
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
01 Oct 2025 12:00 GMT
… that Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics, will … sciences, including biotech and pharma CEOs, heads of research and development … De Backer (CEO, Vir Bio), Stu Mackey (Global Head, BD, Daiichi Sankyo), Sally …
-
Laura McMullin of Daiichi Sankyo named as new ABPI Vice-President
21 Jul 2025 14:20 GMT
… .
Laura is General Manager at Daiichi Sankyo UK, where she leads the … McMullin, ABPI Vice-President and Daiichi Sankyo General Manager said: “It’s … the future.”
Richard Torbett, ABPI Chief Executive said: “We’re delighted to …
-
AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway
02 Jul 2025 19:07 GMT
… oncology business, and president and CEO, Daiichi Sankyo, said, “With today’s accelerated …
-
Astellas Korea appoints ex-Daiichi Sankyo exec as market access head
01 Jul 2025 08:31 GMT
… multinational pharmaceutical companies, including Daiichi Sankyo Korea, Sanofi Korea, and … the oncology division at Daiichi Sankyo Korea, where she … Growth" category of Daiichi Sankyo’s Core Behavior Award, … need it,” Astellas Korea CEO Kim Jun-il said. …
-
AstraZeneca-Daiichi Sankyo Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
26 Jun 2025 07:23 GMT
… Business, and President and CEO, Daiichi Sankyo, Inc, said, “ … ADC) discovered by Daiichi Sankyo and being jointly developed … AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating … ADC. Designed using Daiichi Sankyo’s proprietary DXd …
-
AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC
25 Jun 2025 03:46 GMT
… , and president and CEO, Daiichi Sankyo, Inc, said: … AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are … Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo … Datroway in collaboration Daiichi Sankyo; Orpathys (savolitinib) …
-
Kriti Sanon becomes first Indian celebrity to address WHS
15 Oct 2025 16:53 GMT
… , UNFPA), Hiroyuki Okuzawa (president & CEO, Daiichi Sankyo, Japan), and Budi Gunadi Sadikin …
-
Cancer drug startup Tubulis raises $361 million for ADCs
15 Oct 2025 15:39 GMT
… clinical success of AstraZeneca and Daiichi Sankyo’s Enhertu. The drug has … . According to Dominik Schumacher, Tubulis’ CEO, the biotech has developed a … into.
Dominik Schumacher is the CEO of Tubulis, a German antibody …
-
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
04 Jun 2025 22:13 GMT
… Daiichi Sankyo executive took over as the Japanese drugmaker’s new CEO … antibody-drug conjugates Daiichi Sankyo’s developing with … January, AstraZeneca and Daiichi Sankyo have narrowed their … Okuzawa to navigate Daiichi Sankyo through broader economic …
About
© 1995-2025